Affiliation:
1. Pharmacy , Institut de Cancérologie de l’Ouest Paul Papin , 15 Rue Bocquel , Angers , France
Abstract
Abstract
Intrathecal analgesia has increased over the last 30 years. In oncology, it is a real alternative for the treatment of refractory pain. The diversity of the molecules alone or in combination that can be used, the risk related to the route of administration, and the cost of certain molecules are all arguments in favor of centralized preparation within the pharmacy. The purposes of this work are first of all to explain the reasons for centralization of these preparations, and in a second time to describe the circuit developed within our establishment.
Subject
Pharmacology (medical),Pharmacology,Pharmacy
Reference26 articles.
1. Bhatia G, Lau ME, Koury KM, Gulur P. Intrathecal drug delivery (ITDD) systems for cancer pain. F1000Research. 2014 Jul;2. doi: https://doi.org/10.12688/f1000research.2-96.v4.
2. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain 1995;63:65–76.
3. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001;93:247–57.
4. Association Francophone des Soins Oncologiques de Support. Référentiels en soins oncologiques de support - Prise en charge de la douleur : antalgie intrathécale. 2014. Available at: http://www.afsos.org/liste-complete-referentiels/. Accessed: 01 Nov 2017.
5. Davis MP, Walsh D, Lagman R, LeGrand SB. Randomized clinical trial of an implantable drug delivery system. J Clin Oncol 2003;21:2800–01.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献